C. Twelves

发表

Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients.

F M Blows, E Provenzano, C Caldas, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Improvements in survival for women with breast cancer in Scotland between 1987 and 1993: impact of earlier diagnosis and changes in treatment.

D. Brewster, C. Twelves, C. Thomson, 2004, European journal of cancer.

Variation in survival of women with breast cancer: Health Board remains a factor at 10 years

D. Brewster, C. Twelves, J. Dewar, 2001, British Journal of Cancer.

A Cancer Research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen

A. Howell, T. Powles, M. Dowsett, 2004, Cancer Chemotherapy and Pharmacology.

Entry into clinical trials in breast cancer: the importance of specialist teams. Scottish Breast Cancer Focus Group and Scottish Cancer Therapy Network.

J. Young, C. Twelves, C. Thomson, 1998, European journal of cancer.

Socio-economic deprivation and stage of disease at presentation in women with breast cancer.

S. Ross, A. McConnachie, G. Watt, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Capecitabine named-patient programme for patients with advanced breast cancer. the UK experience.

R. Salazar, D. Cameron, A. Chaturvedi, 2001, European journal of cancer.

Phase I Cancer Clinical Trials: A Practical Guide

M. Buyse, E. Eisenhauer, C. Twelves, 2006 .

Doxorubicin-induced cardiotoxicity.

J. Silber, L. Paz-Ares, G. Barber, 1995, The New England journal of medicine.

Prognostic factors in women with breast cancer: distribution by socioeconomic status and effect on differences in survival

D. Hole, D. Brewster, C. Twelves, 2001, Journal of epidemiology and community health.

Chromosome instability and benefit from adjuvant anthracyclines in breast cancer

J. Bartlett, D. Cameron, A. Munro, 2012, British Journal of Cancer.

Abstract P6-13-01: Impact of the Number of Prior Chemotherapy Regimens on Overall Survival (OS) among Subjects with Locally Recurrent or Metastatic Breast Cancer Treated with Eribulin Mesylate: Results from the Phase III EMBRACE Study

J. Wanders, S. Seegobin, J. Blum, 2010 .

Doxorubicin in advanced breast cancer: influence of schedule on response, survival and quality of life.

A. Howell, P. Hopwood, R. Swindell, 1992, European journal of cancer.

Mathematical and computational models of drug transport in tumours

R M Phillips, S W Smye, B D Sleeman, 2014, Journal of The Royal Society Interface.

Chromosome 17 polysomy (Ch17) as a predictor of anthracycline response: emerging evidence from the UK NEA Tadjuvant breast cancer trial

C. Caldas, E. Provenzano, H. Earl, 2009 .

Duplication of Chromosome 17 CEP Predicts for Anthracycline Benefit: A Meta-Analysis of 4 Trials.

C. Desmedt, D. Larsimont, C. Caldas, 2009 .

BUBR1 and MAD2: Novel Markers for Predicting Benefit from Adjuvant Anthracyclines?

J. Bartlett, D. Cameron, A. Munro, 2009 .

Drug delivery in a tumour cord model: a computational simulation.

M. E. Hubbard, M. Hubbard, P. Loadman, 2017, Royal Society open science.

Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials

C. Caldas, E. Provenzano, H. Earl, 2012, British Journal of Cancer.

Explorer Adjuvant epirubicin followed by cyclophosphamide , methotrexate and fluorouracil ( CMF ) vs CMF in early breast cancer : results with over 7 years median follow-up from the randomised phase III NEAT / BR 9601 trials

C. Caldas, E. Provenzano, P. Pharoah, 2018 .

Variation in the survival of women with breast cancer in Scotland. The Scottish Breast Cancer Focus Group and The Scottish Cancer Therapy Network.

C. Twelves, J. Dewar, C. Thomson, 1998, British Journal of Cancer.

Chromosome 17 polysomy: a unifying hypothesis underlying benefit from adjuvant anthracyclines

C. Desmedt, D. Larsimont, J. Isola, 2009 .

A phase II, multicentre, UK study of vinorelbine in advanced breast cancer.

A. Curnow, N. Dobbs, C. Twelves, 1994, British Journal of Cancer.

Breast cancer, locally advanced and metastatic

L. Holmberg, O. Nanni, S. Barni, 2012 .

Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer

S. Kaye, D. Bisset, P. Vasey, 2002, British Journal of Cancer.

The response of cerebral metastases in small cell lung cancer to systemic chemotherapy.

H. Earl, R. Souhami, D. Geddes, 1990, British Journal of Cancer.

A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer.

H. Mackay, R. Glasspool, D. Cunningham, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Chemotherapy of advanced breast cancer: outcome and prognostic factors.

R. K. Knight, W. Gregory, C. Twelves, 1993, British Journal of Cancer.

The value of health-related quality of life assessment in cancer clinical trials

P. Fargeot, C. Coens, F. Efficace, 2007 .

Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer

N. Dobbs, C. Twelves, R. Rubens, 1991, Cancer Chemotherapy and Pharmacology.